170861-68-4

Basic information

• Product Name: 2-(5-methyl-2-phenyloxazol-4-yl)ethyl 4-methylbenzenesulfonate
• Synonyms: 2-(5-methyl-2-phenyloxazol-4-yl)ethyl 4-methylbenzenesulfonate
• CAS NO: 170861-68-4
• Molecular Formula: C19H19NO4S
• Molecular Weight: 357.43
• Mol File: 170861-68-4.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 2-(5-methyl-2-phenyloxazol-4-yl)ethyl 4-methylbenzenesulfonate(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(5-methyl-2-phenyloxazol-4-yl)ethyl 4-methylbenzenesulfonate(170861-68-4)
• EPA Substance Registry System: 2-(5-methyl-2-phenyloxazol-4-yl)ethyl 4-methylbenzenesulfonate(170861-68-4)

Safety Data

• Hazardous Substances Data: 170861-68-4(Hazardous Substances Data)

Usage

General Description

2-(5-methyl-2-phenyloxazol-4-yl)ethyl 4-methylbenzenesulfonate is a chemical compound that consists of a 4-methylbenzenesulfonate group attached to a 2-(5-methyl-2-phenyloxazol-4-yl)ethyl group. It is commonly used in the pharmaceutical and chemical industries as an intermediate in the synthesis of various drugs and organic compounds. 2-(5-methyl-2-phenyloxazol-4-yl)ethyl 4-methylbenzenesulfonate has the potential to exhibit biological activity due to its structural similarity to other biologically active molecules. However, more research is needed to fully understand its properties and potential applications. Its synthesis and use should be carried out in accordance with proper safety guidelines and regulations.

Upstream product

• 103788-65-4 (5-methyl-2-phenyloxazol-4-yl)ethanol 
• 98-59-9 p-toluenesulfonyl chloride 
• 103788-64-3 methyl 2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)acetate 
• 105983-77-5 methyl 4-bromo-3-oxopentanoate 
• 104-15-4 toluene-4-sulfonic acid 
• 107367-98-6 2-(5-Methyl-2-phenyl-4-oxazolyl)-acetic acid 
• 103788-61-0 (5-methyl-2-phenyl-4-oxazolyl)methyl chloride 
• 100-52-7 benzaldehyde 
• 27492-46-2 4,5-dimethyl-2-phenyl-oxazole 3-oxide 
• 4124-41-8 p-toluenesulfonylanhydride 

Downstream Products

• 312690-34-9 2-[1-{4-[2-(5-Methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-meth-(E)-ylidene]-4-(3aR,7aS)-octahydro-isoindol-2-yl-4-oxo-butyric acid ethyl ester 
• 501031-55-6 4-(2-Azido-ethyl)-5-methyl-2-phenyl-oxazole 
• 478541-05-8 4-methyl-3-nitro-benzenesulfonic acid 2-[5-methyl-2-(4-nitro-phenyl)-oxazol-4-yl]-ethyl ester 
• 748154-36-1 5-methyl-4-[2-(2-methyl-3-nitrophenoxy)ethyl]-2-phenyl-1,3-oxazole 
• 853077-05-1 4-(2-methoxycarbonylethyl)-7-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]-1,3-dihydroisoindole-2-carboxylic acid t-butyl ester 
• 501031-35-2 5-Benzyloxy-1-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethyl]-1H-indole 
• 403612-12-4 2-Methyl-2-{3-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenoxy}propionic Acid Ethyl Ester 
• 403612-64-6 2-{2-Benzyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenoxy}-2-methylpropionic Acid Ethyl Ester 
• 403612-13-5 2-Methyl-2-{2-methyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenoxy} Propionic Acid Ethyl Ester 
• 403612-78-2 2-{2-hydroxymethyl-4-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenoxy}-2-methylpropionic acid Ethyl Ester 
• 403612-19-1 {4-[2-(5-Methyl-2-phenyloxazol-4-yl)ethoxy]-2-propylphenoxy}acetic Acid Ethyl Ester 
• 403612-30-6 4-[2-(2,6-Diallyl-4-benzyloxy-phenoxy)-ethyl]-5-methyl-2-phenyl-oxazole 
• 403612-28-2 {4-[2-(5-Methyl-2-phenyl-oxazol-4-yl)-ethoxy]-2,6-dipropyl-phenoxy}-acetic Acid Ethyl Ester 
• 403610-49-1 2-{2-Butyl-5-[2-(5-methyl-2-phenyloxazol-4-yl)ethoxy]phenoxy}-2-methylpropionic Acid 

Relevant articles and documents

SUBSTITUTED HETEROCYCLIC DERIVATIVES AS GPR AGONISTS AND USES THEREOF

The present invention generally relates to substituted heterocyclic derivatives (the compounds of Formula (I)), processes for their preparation, pharmaceutical compositions containing said compounds, their use as G-protein coupled receptor (GPR) agonists, particularly as GPR40 agonists and methods of using these compounds in the treatment of GPR40 mediated diseases or conditions such as Type 2 diabetes, obesity, dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

Conversion of human-selective PPARα agonists to human/mouse dual agonists: A molecular modeling analysis

To understand the species selectivity in a series of α-methyl- α-phenoxy carboxylic acid PPARα/γ dual agonists (1-11), structure-based molecular modeling was carried out in the ligand binding pockets of both human and mouse PPARα. This study suggested that interaction of both 4-phenoxy and phenyloxazole substituents of these ligands with F272 and M279 in mouse PPARα leads to the species-specific divergence in ligand binding. Insights obtained in the molecular modeling studies of these key interactions resulted in the ability to convert a human-selective PPARα agonist to a human and mouse dual agonist within the same platform.

OXAZOLE-DERIVATIVES AS PPAR AGONISTS

Fused heteroaryl carboxylic acids of formula (I): wherein R1, Ar, A, Y, HET, Q, and T are as defined in the specification; pharmaceutical compositions containing effective amounts of said compounds or their salts are useful for treating PPAR related disorders, such as diabetes, dyslipidemia, obesity and inflammatory disorders.